by Lance Smith | Mar 24, 2020 | Study Scavenger Clinical Trial Recruitment Platform
ENGLEWOOD, Colo., March 24, 2020 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE; the “Company”), a pre-revenue development stage biopharmaceutical company announced today that it has suspended patient enrollment in its Phase 3...by Lance Smith | Mar 24, 2020 | Study Scavenger Clinical Trial Recruitment Platform
COVID-19 task force established to support enrolled patients Participating medical centers implemented safety measures and currently enrolling patients Cranbury, NJ, March 24, 2020 (GLOBE NEWSWIRE) — Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a...by Lance Smith | Mar 24, 2020 | Study Scavenger Clinical Trial Recruitment Platform
It is more important than ever to take care of one another and be diligent and wise in our daily activities. This press release was orginally distributed by SBWire Santa Ana, CA — (SBWIRE) — 03/24/2020 — Per the FDA Guideline on Conduct of Clinical...by Lance Smith | Mar 24, 2020 | Study Scavenger Clinical Trial Recruitment Platform
ClinOne, an industry leader in remote clinical trial patient management, added the CU Healthcare Innovation Fund as the lead investor for their Series-A financing, with a first closing of $3.6 million. The fund is affiliated with the Anschutz Medical Campus in Denver...by Lance Smith | Mar 24, 2020 | Study Scavenger Clinical Trial Recruitment Platform
European site enrollment concerns grow to 85% Over the course of just one week, US clinical research study sites’ concern about COVID-19-related interruptions to recruitment and retention has increased by 124%, jumping from 25% to 56% according to an ongoing...by Lance Smith | Mar 24, 2020 | Study Scavenger Clinical Trial Recruitment Platform
Trial also achieves statistical significance in key secondary endpoints Novavax to submit a U.S. BLA under FDA’s accelerated approval pathway Company to host investor conference call today at 8:30 a.m. EDT GAITHERSBURG, Md., March 24, 2020 (GLOBE NEWSWIRE)...